(Reuters) - THP had developed a transgenic mammalian platform to create human antibodies, which would enable Roche to generate both monoclonal and polyclonal antibody therapeutics with enhanced efficiency, the Swiss group said.
Read more at Reuters.com Mergers News
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment